Onesource Specialty Pharma Ltd. (ONESOURCE) fundamentals
Onesource Specialty Pharma Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ONESOURCE (ISIN INE013P01021). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Onesource Specialty Pharma Ltd. does
OneSource Specialty Pharma Limited is an India-based vertically integrated biopharma service company with the capabilities to develop and manufacture complex biologics, biosimilars and vaccines. It operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO). The Company specializes in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors. Its integrated services offer comprehensive biologics solutions. It supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. The Company caters to a variety of capsule shapes and sizes, as well as formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories.
Valuation and market data
| Last close | ₹1334.10 |
|---|---|
| Market capitalisation | ₹15,288 crore |
| Enterprise value | ₹16,187 crore |
| P/E (TTM) | 0.00 |
| Price to book | 2.62 |
| Price to sales (TTM) | 6.00 |
| Book value per share | ₹508.86 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Jan 24 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,437 crore | ₹-92 crore | ₹-74 crore | -6.44 |
| Mar 2025 | ₹1,462 crore | ₹-67 crore | ₹-17 crore | -1.63 |
| Mar 2024 | ₹176 crore | ₹-366 crore | ₹-366 crore | -94.15 |
| Mar 2023 | ₹41 crore | ₹-416 crore | ₹-416 crore | -200.87 |
| Mar 2022 | ₹136 crore | ₹-231 crore | ₹-231 crore | -65.25 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 30.5% |
|---|---|
| Foreign institutions (FII) | 19.5% |
| Mutual funds | 13.8% |
| Other domestic institutions | 10.4% |
| Retail and others | 25.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.